Oral Encochleated Amphotericin B (CAMB)

DRUG3 trials

Sponsors

Matinas BioPharma Nanotechnologies, Inc.

Conditions

Acute Lymphoblastic LeukemiaAcute Myeloid LeukemiaCandidiasis, VulvovaginalVulvovaginal CandidiasesVulvovaginitisYeast InfectionYeast Infection Vaginal

Phase 2

Safety and Efficacy of Oral Encochleated Amphotericin B (CAMB/MAT2203) in the Treatment of Vulvovaginal Candidiasis (VVC)

CompletedNCT02971007

Matinas BioPharma Nanotechnologies, Inc.Candidiasis, Vulvovaginal, Vulvovaginitis, Yeast Infection +1

Start: 2016-11-30End: 2017-05-31Updated: 2018-11-02

Efficacy and Safety of Oral Encochleated Amphotericin B (CAMB) in the Treatment of Fluconazole-Resistant Vulvovaginal Candidiasis

WithdrawnNCT03167957

Matinas BioPharma Nanotechnologies, Inc.Candidiasis, Vulvovaginal, Vulvovaginal Candidiases, Vulvovaginitis +2

Start: 2019-12-31End: 2020-12-31Updated: 2019-03-08

Safety and PK of Oral Encochleated Amphotericin B (CAMB/MAT2203) for Antifungal Prophylaxis in Patients Undergoing Induction Chemotherapy for Acute Myelogenous and Lymphoblastic Leukaemia

WithdrawnNCT03187691

Matinas BioPharma Nanotechnologies, Inc.Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia

Start: 2019-08-31End: 2020-12-31Updated: 2019-03-08

Related Papers

Phase I EnACT Trial of the Safety and Tolerability of a Novel Oral Formulation of Amphotericin B.

2020-09-2140 citations